Topics

UCB to Acquire Ra Pharmaceuticals for $2.5 Billion, Expanding its Rare Disease Drug Pipeline

13:06 EDT 10 Oct 2019 | Speciality Pharma Journal

BRUSSELS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive US$ 48 in cash for each Ra Pharma share at …

Original Article: UCB to Acquire Ra Pharmaceuticals for $2.5 Billion, Expanding its Rare Disease Drug Pipeline

NEXT ARTICLE

More From BioPortfolio on "UCB to Acquire Ra Pharmaceuticals for $2.5 Billion, Expanding its Rare Disease Drug Pipeline"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...